News and Press Releases
IMAAVY (nipocalimab)▼shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)
Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving sustained minimal symptom expression (MSE)...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 22, 2026
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)
Phase 1b dataset with LYT-200 demonstrates complete responses and favorable tolerability across both R/R HR-MDS and R/R AML PureTech’s Founded Entity, Gallop Oncology, to advance LYT-200 first in R/R HR-MDS,...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 22, 2026
AES Cleanroom Technology Marks 40 Years of Innovation at INTERPHEX 2026
21 April 2026 -- Pennsylvania, US -- AES Cleanroom Technology, a leading provider of modular cleanroom design, manufacturing, and construction solutions for the life sciences and biopharmaceutical industries, is celebrating...
Category: Biotechnology, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: April 21, 2026
Health Economic Analysis Shows Early Use of Fast Diagnostics in Sepsis Care Could Prevent 5,200 Deaths in the UK and Save theNHS £300 Million Annually
Every year, an estimated 104,000 adults in the UK are hospitalised with bloodstream infections at high risk of progressing to sepsis – a quickly deteriorating condition that claims more lives...
Category: Drug Discovery, Other, Pharmaceutical
Posted: April 20, 2026
Chineham Gate Crockford Lane Chineham Park Basingstoke Hampshire RG24 8NA
U.S. FDA Grants Priority Review to sBLA for PADCEV + Keytruda as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial Building on the existing indication in cisplatin-ineligible muscle-invasive bladder cancer (MIBC), if approved, this...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: April 20, 2026
Samsung Bioepis Presents Nonclinical Data for its First Novel Antibody-Drug Conjugate Candidate SBE303 at AACR 2026
Nonclinical findings from pharmacology, pharmacokinetics, and toxicology studies support the advancement of SBE303 into clinical development with a favorable therapeutic index (TI), with its first-in-human Phase I clinical trial began...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 20, 2026
Integrated DNA Technologies Expands Coralville Manufacturing Footprint to Support Growing Global Demand for MRD Solutions
Expanded footprint delivers speed, scale and customization minimal residual disease (MRD) innovators need without compromising quality Increased production capacity leverages IDT’s highly specialized, high-throughput manufacturing platform. 20 April 2026 --...
Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: April 20, 2026
Kahimmune Therapeutics signs agreement for scientific collaboration with Gustave Roussy
Agreement will enable selection of Kahimmune’s first companion neoantigen therapy candidate against colorectal cancer and pancreatic cancer, with financial support from Bpifrance Kahimmune exploits dark genome to develop next-generation...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 18, 2026
Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026
Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies and key biomarkers identified AT-108 combines the advantages of an off-the-shelf gene therapy whilst offering a...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2026
Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure
FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints met Clinically meaningful microbiome modulation observed, including significant improvement up to 6-month follow-up Results...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 16, 2026
STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15
The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications First‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation 16 April...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 16, 2026
Building the Future of Biotechnology — UK Biotech Day 2026
15 April 2026 -- London, UK -- UK Biotech Day 2026, taking place on 27–28 May 2026, will be held at the Radisson Hotel & Conference Centre London Heathrow. The...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 15, 2026
Building A, Bath Road, Heathrow Boulevard, Sipson UB7 0DU, London, UK
ELRIG Announces Inaugural US Drug Discovery Conference
Free-to-attend event takes place at Pfizer in Cambridge, MA from 16–17 June Drug Discovery USA 2026 to focus on emerging multifunctional small molecule and biologic approaches to drug difficult targets....
Category: Drug Discovery, Other, Pharmaceutical
Posted: April 14, 2026
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK
Vetter Strengthens its Global Clinical Manufacturing Network with Strategic Site Enhancements
Ravensburg, April 14, 2026: Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), announced significant progress in the continued expansion of its global clinical manufacturing network. With the ongoing...
Category:
Posted: April 14, 2026
OBN rebrands to BioUK in alignment with its mission to catalyse success in UK life sciences
Oxford and London, UK, 14 April 2026: OBN (UK) Ltd., the not-for-profit membership organisation focused on catalysing success UK life sciences, today announced that it is changing its name to...
Category:
Posted: April 14, 2026
